Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs

被引:69
|
作者
Fossati, Lina [1 ]
Dechaume, Rachel [1 ]
Hardillier, Emmanuel [1 ]
Chevillon, Delphine [1 ]
Prevost, Colette [1 ]
Bolze, Sebastien [1 ]
Maubon, Nathalie [1 ]
机构
[1] Labs Fournier, Preclin Candidate Select Unit, F-21121 Daix, France
关键词
Caco-2; cells; absorption assay; FaSSIF; transport; lipophilic acid drugs;
D O I
10.1016/j.ijpharm.2008.04.034
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The most commonly used method to assess intestinal permeability is the measurement of compound flux across a Caco-2 cells monolayer by using Hanks balanced salt solution (HBSS)-like buffers. Nevertheless, lipophilic acid drugs are poorly or not at all soluble in these types of buffers and their adsorption on the transwell plate is commonly observed. To reduce adsorption and increase solubility, permeability assays need to be developed in conditions other than classic conditions for lipophilic compounds. The best model to increase recovery of lipophilic compounds was determined as fasted state simulated intestinal fluid (FaSSIF) in the apical compartment and HBSS with 1% bovine serum albumin (BSA) in basolateral compartment. This model allows a correlation between absorption on Caco-2 cells and absorbed fraction in humans. For 35 compounds, only 2 outliers were observed in the Caco-2 assay using the FaSSIF model. These two outliers were the same outlier compounds as those observed with a classic Caco-2 method. Furthermore, a permeability assay of Pgp substrates evidenced efflux transport in both models and addition of a Pgp inhibitor suppressed Pgp efflux transport. FaSSIF in the apical compartment and HBSS with 1 % BSA in the basolateral compartment is the model of choice to predict in vivo absorption for lipophilic acid drugs. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:148 / 155
页数:8
相关论文
共 50 条
  • [31] EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2)
    ARTURSSON, P
    LINDMARK, T
    DAVIS, SS
    ILLUM, L
    PHARMACEUTICAL RESEARCH, 1994, 11 (09) : 1358 - 1361
  • [32] Variability in Caco-2 and MDCK cell-based intestinal permeability assays
    Volpe, Donna A.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (02) : 712 - 725
  • [33] Caco-2 Cellular Model to Study In Vitro the Mechanisms of Intestinal Barrier Permeability
    V. V. Furman
    S. B. Semenova
    Cell and Tissue Biology, 2025, 19 (2) : 125 - 129
  • [34] Permeability and Conjugative Metabolism of Flaxseed Lignans by Caco-2 Human Intestinal Cells
    Mukker, Jatinder Kaur
    Michel, Deborah
    Muir, Alister D.
    Krol, Ed S.
    Alcorn, Jane
    JOURNAL OF NATURAL PRODUCTS, 2014, 77 (01): : 29 - 34
  • [35] Cytotoxicity and intestinal permeability of phycotoxins assessed by the human Caco-2 cell model
    Qiu, Jiangbing
    Zhang, Jingrui
    Li, Aifeng
    ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2023, 249
  • [36] Effect of common excipients on Caco-2 transport of low-permeability drugs
    Rege, BD
    Yu, LX
    Husain, AS
    Polli, JE
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (11) : 1776 - 1786
  • [37] Addition of Optimized Bovine Serum Albumin Level in a High-Throughput Caco-2 Assay Enabled Accurate Permeability Assessment for Lipophilic Compounds
    Cai, Xianmei
    Madari, Shilpa
    Walker, Aaron
    Paiva, Anthony
    Li, Ying
    Herbst, John
    Shou, Wilson
    Weller, Harold
    SLAS DISCOVERY, 2019, 24 (07) : 738 - 744
  • [38] Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery
    Kerns, EH
    Di, L
    Petusky, S
    Farris, M
    Ley, R
    Jupp, P
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (06) : 1440 - 1453
  • [39] Investigation of the intestinal absorption of immunosuppressive drugs using the human intestinal Caco-2 cell line
    Boussera, B.
    Picard, N.
    Liagre, B.
    Beneytout, J. L.
    Marquet, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 45 - 45
  • [40] Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2
    Krishna, G
    Chen, KWJ
    Lin, CC
    Nomeir, AA
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 222 (01) : 77 - 89